Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Lymphoma 2Prostatic Neoplasms 1Melanoma 1Lymphatic Diseases 1Burkitt Lymphoma 1

Interventions

Vorinostat 3Azacitidine 3venetoclax 2trametinib 2ruxolitinib 2pertuzumab 2palbociclib 2olaparib 2durvalumab 2dabrafenib 2copanlisib 2aflibercept 2abiraterone 2Sunitinib 2Specimen Handling 2Sirolimus 2Nivolumab 2Immunoglobulin G 2HhAntag691 2Doxorubicin 2Disulfides 2Dasatinib 2Cyclophosphamide 2Biopsy 2Afatinib 2Ado-Trastuzumab Emtansine 22C4 antibody 2ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × sepantronium × Lymphoid × Clear all
NCT00818480 2015-09-04

An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

Astellas Pharma Inc

Phase 2 Completed
10 enrolled
DermatologicGenitourinaryLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡